Oracle Stock Drops 6.64% But UBS and ScotiaBank Stand Firm With Raised Price Targets

By TrendSpider Editor

Oracle Corporation is under notable selling pressure on Wednesday, June 3, 2026, falling 6.64% to $228.30, yet two major Wall Street firms are holding their ground and raising their price targets on the stock. UBS lifted its target to $285 from $250, while ScotiaBank made an even bolder move, hiking

Oracle Stock Drops 6.64% But UBS and ScotiaBank Stand Firm With Raised Price Targets

Oracle Corporation is under notable selling pressure on Wednesday, June 3, 2026, falling 6.64% to $228.30, yet two major Wall Street firms are holding their ground and raising their price targets on the stock. UBS lifted its target to $285 from $250, while ScotiaBank made an even bolder move, hiking its target to $290 from $215, both maintaining buy ratings. The stock is trading well off its 52-week high of $345.72 but remains substantially above its 52-week low of $134.57, suggesting the long-term uptrend remains structurally intact despite today's pain.

Key Drivers of the ORCL Stock Move

• Main Catalyst: Two analyst confirmations headlined today's action. UBS analyst Karl Keirstead reaffirmed his buy rating and raised his price target by $35 to $285, while ScotiaBank analyst Patrick Colville confirmed buy and dramatically raised his target by $75 to $290. Neither firm flinched despite the sharp intraday selloff.
• Bull Case: The average price target across these two actions sits at $287.50, representing upside of roughly 26% from the current price of $228.30. ScotiaBank's target revision from $215 to $290 is particularly aggressive and signals growing conviction in Oracle's fundamental trajectory even amid today's volatility.
• Bear Case: Despite the analyst support, ORCL is shedding more than 6% in a single session and sits approximately 34% below its 52-week high of $345.72. The magnitude of today's decline suggests the market is pricing in a meaningful risk event or disappointment that analyst price target revisions alone may not immediately offset.

The forward setup for Oracle is a study in contrasts. On one hand, two buy-side analysts are raising targets on the same day the stock is getting hit hard, which historically can signal that institutional conviction is building into weakness rather than fading. The average price target of $287.50 gives long-term investors a clear benchmark to watch. On the other hand, a 6.64% single-session drop is not noise, and traders will be watching whether $228.30 holds as near-term support or whether the stock continues to slide toward the lower end of its 52-week range. With Oracle's 52-week range spanning $134.57 to $345.72, the stock has room to move in either direction, making the analyst confidence either prescient or premature depending on how the next few sessions unfold.

ORCL Analyst Ratings and Price Targets

• UBS (Karl Keirstead): Confirmed buy rating. Price target raised to $285 from a prior $250.
• ScotiaBank (Patrick Colville): Confirmed buy rating. Price target raised to $290 from a prior $215, a $75 increase and the largest revision of the two actions.

The consensus across today's two rating actions reflects a buy stance, with an average price target of $287.50. Both revisions are upward, suggesting analysts see the current price level as an opportunity rather than a warning sign.

ORCL Seasonality

Early June has historically coincided with Oracle's fiscal year-end reporting period, which tends to draw heightened analyst activity and elevated volatility as Wall Street recalibrates models ahead of or immediately following earnings releases. Single-session swings of this magnitude in early June are not historically unusual for ORCL.

ORCL Relative Performance

Oracle's 6.64% decline on June 3, 2026, stands out as a significant underperformer relative to broader market norms for a single session. While peer and index comparison data are not available in today's dataset, a move of this size places ORCL firmly in the big-loser category for the session, drawing attention from momentum traders and long-term value investors alike given the stock's current positioning between its 52-week low of $134.57 and high of $345.72.